Angiotensin-converting enzyme (ACE), a key component of the renin-angiotensin-aldosterone system is involved in blood pressure regulation through vasoconstriction and predominantly found on surface of lung capillary endothelial cells. Due to the frequently elevated ACE activity in acute sarcoidosis, assessment of ACE levels serves as a valuable biomarker for diagnosis and therapeutic monitoring.

DiaSys ACE FS is an enzyme-based colorimetric assay representing a novel, redefined version of the traditional hippuric acid method. It is specifically designed for accurate measurement of ACE activity using minimal volumes of human serum or lithium heparin plasma. Unlike the classical hippuric acid assay, which requires reconstitution, DiaSys ACE FS offers a ready-to-use, two-component format with excellent onboard stability. Its compatibility with all clinical chemistry analyzers ensures integration into laboratory workflows.

Assays based on the synthetic tripeptide furylacryloyl-phenylalanyl-glycyl-glycine (FAPGG) are another widely available commercial method for routine ACE activity testing. However, FAPGG method is highly vulnerable to analytical errors. The method’s low signal output results in poor precision, and it is particularly susceptible to interference from lipemia and bilirubin often leading to inaccurate patient results. In contrast, DiaSys ACE FS offers a robust and reliable alternative. With its high absorbance signals, ACE FS ensures excellent accuracy and precision, effectively overcoming the limitations and susceptibility to interference associated with the FAPGG assay.